Cargando…

Phase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: a SFOP study

The maximum tolerated dose of paclitaxel administered by 24-hour continuous infusion in children is known. Short infusion might offer equivalent antitumour efficacy and reduced haematological toxicity, without increasing the allergic risk. Our aims were to determine the maximum tolerated dose and th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Doz, F, Gentet, J C, Pein, F, Frappaz, D, Chastagner, P, Moretti, S, Vassal, G, Arditti, J, Tellingen, O Van, Iliadis, A, Catalin, J
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2001
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363793/ https://www.ncbi.nlm.nih.gov/pubmed/11237379 http://dx.doi.org/10.1054/bjoc.2000.1637

Ejemplares similares

Combined treatment modality for intracranial germinomas: results of a multicentre SFOP experience
por: Bouffet, E, et al.
Publicado: (1999)

Dose finding and O(6)-alkylguanine-DNA alkyltransferase study of cisplatin combined with temozolomide in paediatric solid malignancies
por: Geoerger, B, et al.
Publicado: (2005)

Treatment of stage 4s neuroblastoma – report of 10 years' experience of the French Society of Paediatric Oncology (SFOP)
por: Schleiermacher, G, et al.
Publicado: (2003)

Mortality in Children with Optic Pathway Glioma Treated with Up-Front BB-SFOP Chemotherapy
por: Rakotonjanahary, Josué, et al.
Publicado: (2015)

A phase I study of intravenous liposomal daunorubicin (DaunoXome) in paediatric patients with relapsed or resistant solid tumours
por: Lowis, S, et al.
Publicado: (2006)

Unresectable localized neuroblastoma: improved survival after primary chemotherapy including carboplatin-etoposide. Neuroblastoma Study Group of the SociÃ©tÃ© FranÃ§aise d'Oncologie PÃ©diatrique (SFOP).
por: Rubie, H., et al.
Publicado: (1998)

Phase I and Pharmacokinetic Study of Paclitaxel by 24‐Hour Intravenous Infusion
por: Tamura, Tomohide, et al.
Publicado: (1994)

Neuromuscular toxicities of paclitaxel 210 mg m(-2) by 3-hour infusion.
por: Kunitoh, H., et al.
Publicado: (1998)

Pharmacodynamic Modeling of the Entire Time Course of Leukopenia after a 3‐Hour Infusion of Paclitaxel
por: Minami, Hironobu, et al.
Publicado: (2001)

Phase I Study of Paclitaxel by Three‐hour Infusion: Hypotension Just after Infusion Is One of the Major Dose‐limiting Toxicities
por: Tamura, Tomohide, et al.
Publicado: (1995)

An evaluation of continuous subcutaneous infusions across seven NHS acute hospitals: is there potential for 48-hour infusions?
por: Baker, J., et al.
Publicado: (2020)

A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer
por: Kollmannsberger, C, et al.
Publicado: (2000)

A Phase 1 Trial of pharmacologic interactions between transdermal selegiline and a 4-hour cocaine infusion
por: Harris, Debra S, et al.
Publicado: (2009)

Paclitaxel in self-micro emulsifying formulations: oral bioavailability study in mice
por: Oostendorp, Roos L., et al.
Publicado: (2010)

Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients
por: Tellingen, O van, et al.
Publicado: (1999)

A Case of Stress Cardiomyopathy With Nab-Paclitaxel Infusion
por: Singh, Harjinder, et al.
Publicado: (2023)

Nonengraftment donor lymphocyte infusions for refractory acute myeloid leukemia
por: Reagan, J L, et al.
Publicado: (2015)

Long-term visual acuity in patients with optic pathway glioma treated during childhood with up-front BB-SFOP chemotherapy—Analysis of a French pediatric historical cohort
por: Rakotonjanahary, Josué, et al.
Publicado: (2019)

Clinical pharmacokinetics of etoposide during 120 hours continuous infusions in solid tumours.
por: Desoize, B., et al.
Publicado: (1990)

The pharmacological bases of the antiangiogenic activity of paclitaxel
por: Bocci, Guido, et al.
Publicado: (2013)

Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.
por: van Asperen, J., et al.
Publicado: (1997)

Histological, cytological and immunological analyses are complementary for the detection of neuroblastoma cells in bone marrow.
por: Favrot, M. C., et al.
Publicado: (1986)

Stroke Recovery in Rats after 24‐Hour–Delayed Intramuscular Neurotrophin‐3 Infusion
por: Duricki, Denise A., et al.
Publicado: (2018)

The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients
por: Malingré, M M, et al.
Publicado: (2001)

Labetalol infusion for refractory hypertension causing severe hypotension and bradycardia: an issue of patient safety
por: Fahed, Samir, et al.
Publicado: (2008)

Micropropagation of orchids /
por: Arditti, Joseph
Publicado: (2008)

Setting-up a small observatory: from concept to construction
por: Arditti, David
Publicado: (2008)

Circadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion
por: Fleming, Gini F, et al.
Publicado: (2015)

Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience.
por: Gore, M. E., et al.
Publicado: (1995)

Propofol Infusion Syndrome in Refractory Status Epilepticus
por: Hwang, Woo Sub, et al.
Publicado: (2013)

Safe and tolerable one-hour pamidronate infusion for multiple myeloma patients
por: Chantzichristos, Dimitrios, et al.
Publicado: (2008)

Paclitaxel-containing high-dose chemotherapy for relapsed or refractory testicular germ cell tumours
por: McNeish, I A, et al.
Publicado: (2004)

MON-098 Risk of Long-Term Endocrine Sequelae in Survivors of Progressing Childhood Optic Pathway Glioma Treated by Upfront Chemotherapy: Preliminary Analyses of 102 Subjects from the French Multicentric BB-SFOP Registry
por: Hippolyte, Helene, et al.
Publicado: (2020)

No need for H(2)-antagonists in premedication regimens for paclitaxel infusions: less is more
por: Gelderblom, Hans, et al.
Publicado: (2021)

Pharmacological Neurorescue in a Paclitaxel-Induced Chemobrain Model
por: Chen, Peng, et al.
Publicado: (2021)

Possible pharmacologic interactions caused by mixed infusion
por: Stögermüller, B, et al.
Publicado: (2008)

Tisagenlecleucel infusion in patients with relapsed/refractory ALL and concurrent serious infection
por: Hall, Erin M, et al.
Publicado: (2021)

Phase I trial with pharmacokinetics of CB10-277 given by 24 hours continuous infusion.
por: Foster, B. J., et al.
Publicado: (1993)

Recurrent extraneural sonic hedgehog medulloblastoma exhibiting sustained response to vismodegib and temozolomide monotherapies and inter-metastatic molecular heterogeneity at progression
por: Petrirena, Gregorio J., et al.
Publicado: (2018)

Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction
por: Berger, Michael J., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_8u6ucij6g5ti7120b23nkj3176